CD274 and melanoma: The upregulation of PD-L1 on melanoma cells was due to sustained exposure to dabrafenib, trametinib, or dabrafenib plus trametinib, and the increased level of PD-L1 may be a biomarker of acquired resistance to these drugs [95].